Sanofi-Aventis acquired Laboratorios Kendrick, a Mexican generic manufacturer. Sanofi hopes the purchase will extend its pharmaceutical portfolio in emerging markets. Laboratorios Kendric recorded sales of approximately $35 million in 2008.
Genzyme struck a deal with Bayer HealthCare to assume “primary responsibility” for the worldwide commercialization of Campath, a multiple sclerosis treatment. Genzyme also picked up Bayer's cancer drugs Fludara and Leukine, and will buy Bayer's Leukine manufacturing plant, near Seattle, for $75 - $100 million.